Skip to main content
. 2022 Oct 4;19(19):12694. doi: 10.3390/ijerph191912694

Table 1.

Subjects’ characteristics.

Patients with PD Controls p Early PD Advanced PD p
Number of subjects (n) 62 40 - 38 24 -
Age (years) 69.46 ± 7.5 67.2 ± 7.7 0.7 69.0 ± 8.6 70.1 ± 5.4 0.6
Gender (male/female) 36/26 15/25 0.07 22/16 14/10 0.8
Mini Mental State Examination 27.15 ± 2.7 28.5 ± 1.7 0.003 27.4 ± 2.7 26.8 ± 2.7 0.34
Counting-backward test 17.25 ± 6.6 12.9 ± 2.7 <0.001 17.2 ± 7.3 17.2 ± 5.6 0.94
Number of enunciated words in dual task 23.54 ± 6.6 28.1 ± 6.0 <0.001 23.5 ± 8.1 23.6 ± 5.7 0.97
Disease duration (years) 5.61 ± 4.8 - - 4.0 ± 2.9 8.17 ± 6.0 <0.001
Levodopa equivalent daily dose (mg) 513.24 ± 442.2 - - 373.9 ± 259.7 699.1 ± 560.0 0.016
Hoehn–Yahr stage (H–Y) (0–4) 2.3 ± 0.9 - - 1.7 ± 0.5 3.25 ± 0.4 <0.001
Stage 1 (n) 12 - - - - -
Stage 2 25 - - - - -
Stage 3 18 - - - - -
Stage 4 6 - - - - -
Rehabilitation treatment
Yes 29 - 16 13
No 32 - 21 11